Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

SELECTED QUARTERLY FINANCIAL DATA

SELECTED QUARTERLY FINANCIAL DATA

12 Months Ended

Dec. 31, 2011

13. SELECTED QUARTERLY FINANCIAL DATA

	(unaudited, in thousands, except per share amounts)

	Year Ended December 31, 2011												Year Ended December 31, 2010
	Q1			Q2			Q3			Q4			Q1			Q2		Q3		Q4
Revenue	$	—		$	395		$	4,355		$	—		$	3,261		$	49,457	$	72,282	$	—
Net income (loss)	$	(20,781	)	$	(21,474	)	$	(17,931	)	$	(25,787	)	$	(22,333	)	$	27,029	$	50,433	$	(17,239	)
Net income (loss) per share:
Basic	$	(0.40	)	$	(0.37	)	$	(0.25	)	$	(0.36	)	$	(0.43	)	$	0.52	$	0.97	$	(0.33	)
Diluted	$	(0.40	)	$	(0.37	)	$	(0.25	)	$	(0.36	)	$	(0.43	)	$	0.51	$	0.96	$	(0.33	)
Weighted average shares used in computing net income (loss) per share:
Basic		52,275			58,272			71,226			71,249			51,964			51,974		52,127		52,152
Diluted		52,275			58,272			71,226			71,249			51,964			52,511		52,769		52,152

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details